BSX icon

Boston Scientific

88.95 USD
+0.29
0.33%
At close Dec 20, 4:00 PM EST
After hours
88.95
+0.00
0.00%
1 day
0.33%
5 days
-2.02%
1 month
-1.35%
3 months
5.99%
6 months
15.52%
Year to date
53.79%
1 year
61.79%
5 years
96.05%
10 years
579.01%
 

About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Employees: 48,000

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 14 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

82% more first-time investments, than exits

New positions opened: 162 | Existing positions closed: 89

18% more repeat investments, than reductions

Existing positions increased: 552 | Existing positions reduced: 467

6% more funds holding

Funds holding: 1,290 [Q2] → 1,363 (+73) [Q3]

6% more capital invested

Capital invested by funds: $103B [Q2] → $109B (+$5.7B) [Q3]

3% less funds holding in top 10

Funds holding in top 10: 36 [Q2] → 35 (-1) [Q3]

3.02% less ownership

Funds ownership: 91.45% [Q2] → 88.42% (-3.02%) [Q3]

30% less call options, than puts

Call options by funds: $661M | Put options by funds: $944M

Research analyst outlook

14 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$90
1%
upside
Avg. target
$102
15%
upside
High target
$110
24%
upside

14 analyst ratings

14 positive
100%
neutral
0%
negative
0%
Truist Securities
Richard Newitter
80% 1-year accuracy
40 / 50 met price target
24%upside
$110
Buy
Maintained
18 Dec 2024
JP Morgan
Robbie Marcus
48% 1-year accuracy
10 / 21 met price target
24%upside
$110
Overweight
Maintained
16 Dec 2024
TD Cowen
Joshua Jennings
42% 1-year accuracy
8 / 19 met price target
24%upside
$110
Buy
Maintained
12 Dec 2024
Citigroup
Joanne Wuensch
55% 1-year accuracy
26 / 47 met price target
20%upside
$107
Buy
Maintained
11 Dec 2024
Wells Fargo
Larry Biegelsen
51% 1-year accuracy
24 / 47 met price target
12%upside
$100
Overweight
Maintained
11 Dec 2024

Financial journalist opinion

Based on 15 articles about BSX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
All You Need to Know About Boston Scientific (BSX) Rating Upgrade to Buy
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Boston Scientific (BSX) Rating Upgrade to Buy
Negative
Reuters
2 days ago
FDA classifies recall of Boston Scientific catheters as 'most serious'
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's catheters used in a type of minimally invasive surgery as "most serious".
FDA classifies recall of Boston Scientific catheters as 'most serious'
Positive
Zacks Investment Research
2 days ago
BSX Trades Near 52-Week High: Does the Stock Hold More Potential?
We believe Boston Scientific is one of those MedTech manufacturers that can be considered as the biggest gainers from the Fed's two successive interest rate cuts in 2024.
BSX Trades Near 52-Week High: Does the Stock Hold More Potential?
Positive
Zacks Investment Research
1 week ago
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Neutral
Zacks Investment Research
1 week ago
Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes
Neutral
Zacks Investment Research
1 week ago
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note
Boston Scientific (BSX) closed the most recent trading day at $90.56, moving +0.4% from the previous trading session.
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note
Neutral
PRNewsWire
1 week ago
Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace
NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Boston Scientific (NYSE: BSX) Global Chief Medical Officer, Kenneth Stein, MD, and Scott Shipman, MD, MPH, Executive Director for the Institute for Population Health. The doctors joined host Jane King to discuss health inequities and Boston Scientific's work to improve access to care for underserved populations.
Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace
Positive
CNBC Television
1 week ago
Jim Cramer talks companies that joined the $100 billion club this year
'Mad Money' host Jim Cramer looks at companies that joined the $100 billion club this year.
Jim Cramer talks companies that joined the $100 billion club this year
Neutral
Zacks Investment Research
2 weeks ago
Boston Scientific (BSX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Boston Scientific (BSX) closed at $90.53 in the latest trading session, marking a -0.34% move from the prior day.
Boston Scientific (BSX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Positive
Kiplinger
3 weeks ago
The Best Large-Cap Stocks to Buy
Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.
The Best Large-Cap Stocks to Buy
Charts implemented using Lightweight Charts™